Progression of Rebound-Associated Vertebral Fractures Following Denosumab Discontinuation Despite Reinstitution of Treatment: Suppressing Increased Bone Turnover May Not Be Enough.
Denosumab
Discontinuation
Fracture
Osteoporosis
Rebound
Journal
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry
ISSN: 1094-6950
Titre abrégé: J Clin Densitom
Pays: United States
ID NLM: 9808212
Informations de publication
Date de publication:
Historique:
received:
16
09
2020
revised:
26
10
2020
accepted:
27
10
2020
pubmed:
22
11
2020
medline:
29
10
2021
entrez:
21
11
2020
Statut:
ppublish
Résumé
Rebound-associated vertebral fractures (RAVFs) could occur in a minority of the patients who discontinue denosumab. In such patients, denosumab is often reinstituted to rapidly suppress bone turnover and avert the risk of additional fractures. Herein we report the cases of 2 patients who sustained RAVFs, and in whom resuming denosumab treatment did not avert the occurrence of new RAVFs a few months later, despite the suppression of bone turnover markers. It seems that denosumab reinstitution cannot completely eliminate the risk of new RAVFs and that the rebound of bone turnover may not be the sole mechanism to explain this phenomenon.
Identifiants
pubmed: 33218880
pii: S1094-6950(20)30141-4
doi: 10.1016/j.jocd.2020.10.014
pii:
doi:
Substances chimiques
Bone Density Conservation Agents
0
Denosumab
4EQZ6YO2HI
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
338-340Informations de copyright
Copyright © 2020 The International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.